[HTML][HTML] Allogeneic CAR-T cells: more than ease of access?
C Graham, A Jozwik, A Pepper, R Benjamin - Cells, 2018 - mdpi.com
Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in
achieving a complete remission in a range of B-cell malignancies, most notably B-acute …
achieving a complete remission in a range of B-cell malignancies, most notably B-acute …
[HTML][HTML] NF-kB and the CLL microenvironment
A O'Donnell, C Pepper, S Mitchell, A Pepper - Frontiers in Oncology, 2023 - frontiersin.org
Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the western
world. Despite the positive clinical effects of new targeted therapies, CLL still remains an …
world. Despite the positive clinical effects of new targeted therapies, CLL still remains an …
Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia
…, T Chevassut, CJ Pepper, AGS Pepper - British journal of …, 2020 - Wiley Online Library
Acute myeloid leukaemia (AML) is the most common adult acute leukaemia with the lowest
survival rate. It is characterised by a build‐up of immature myeloid cells anchored in the …
survival rate. It is characterised by a build‐up of immature myeloid cells anchored in the …
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target
…, T Liloglou, C Pepper, AGS Pepper - Blood, The Journal …, 2021 - ashpublications.org
Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor–targeted
inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in …
inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in …
Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells
S Mele, S Devereux, AG Pepper, E Infante… - Blood …, 2018 - ashpublications.org
CD38 is a transmembrane exoenzyme that is associated with poor prognosis in chronic
lymphocytic leukemia (CLL). High CD38 levels in CLL cells are linked to increased cell migration…
lymphocytic leukemia (CLL). High CD38 levels in CLL cells are linked to increased cell migration…
[HTML][HTML] Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model …
…, T Pertel, F Farzaneh, S Dupouy, A Pepper… - Leukemia, 2021 - nature.com
CD19-targeted autologous chimeric antigen receptor (CAR) T-cell therapy has shown
dramatic response rates in relapsed and refractory patients with B-cell malignancies [1–4]. …
dramatic response rates in relapsed and refractory patients with B-cell malignancies [1–4]. …
[HTML][HTML] The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells
CD4+ T-follicular helper cells are essential for the survival, proliferation, and differentiation
of germinal center B cells and have been implicated in the pathogenesis of follicular …
of germinal center B cells and have been implicated in the pathogenesis of follicular …
[HTML][HTML] Elucidation of focal adhesion kinase as a modulator of migration and invasion and as a potential therapeutic target in chronic lymphocytic leukemia
…, CP Smith, C Fegan, R Johnston, A Pepper, C Pepper - Cancers, 2022 - mdpi.com
Simple Summary Despite the successful introduction of targeted therapies, Chronic
Lymphocytic Leukemia (CLL) remains incurable. This is thought to be partially due to the pro-survival …
Lymphocytic Leukemia (CLL) remains incurable. This is thought to be partially due to the pro-survival …
[HTML][HTML] NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma
…, A Ghodke, J Jones, C Pepper, A Pepper… - Frontiers in …, 2023 - frontiersin.org
Improving treatments for Diffuse Large B-Cell Lymphoma (DLBCL) is challenged by the vast
heterogeneity of the disease. Nuclear factor-κB (NF-κB) is frequently aberrantly activated in …
heterogeneity of the disease. Nuclear factor-κB (NF-κB) is frequently aberrantly activated in …
[HTML][HTML] Targeting the non-canonical NF-κB pathway in chronic lymphocytic leukemia and multiple myeloma
…, S Mitchell, SP Mackay, AGS Pepper, C Pepper - Cancers, 2022 - mdpi.com
Simple Summary This study was designed to investigate the potential for targeting the NF-κB-inducing
kinase, NIK, in two common B-cell malignancies, chronic lymphocytic leukemia (…
kinase, NIK, in two common B-cell malignancies, chronic lymphocytic leukemia (…